COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Radiation Dose Escalation in Locally Advanced Rectal Cancer (RaDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02603302
Recruitment Status : Unknown
Verified June 2016 by Marcos Santos, University of Brasilia.
Recruitment status was:  Recruiting
First Posted : November 11, 2015
Last Update Posted : June 14, 2016
Information provided by (Responsible Party):
Marcos Santos, University of Brasilia

Brief Summary:
This is a one arm study where patients with locally advanced rectal cancer will receive neoadjuvant treatment with escalated dose radiotherapy (with 3D conformal radiotherapy, up to 59,4 Gy) and radiosensitizing chemotherapy. Then, patients will operated (total mesorectal excision) after 8 weeks of interval. Primary endpoint will be pCR (pathologic complete response).

Condition or disease Intervention/treatment Phase
Rectal Cancer Radiation: Dose Escalation Radiotherapy Procedure: Delayed surgery Phase 2

Detailed Description:


Rectal cancer is a highly prevalent disease all over the world. In Brazil, it is the second most common cancer among women (after breast tumors), with an estimated incidence of 17.2 cases per 100,000 inhabitants and is the third most common cancer in men (after prostate and lung cancers), with an estimated incidence of 15.4 cases per 100,000 inhabitants.


The aim of this study is to evaluate the pathologic complete response (pCR) of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant radiochemotherapy (RCT) employing anticancer drugs at standard dose and interval extended to surgery with or without adjuvant neoplastic therapy.


Neoadjuvant chemoradiotherapy with radiation dose escalation associated with radiosensitizing therapy and surgery with a total mesorectal excision (TME), 8 weeks after completing neoadjuvant treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Neoadjuvant Radiotherapy Dose Escalation in Association With Chemotherapy for the Treatment of Locally Advanced Rectal Cancer
Study Start Date : January 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: Locally advanced rectal cancer

RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU

Surgery 8 weeks after the neoadjvuant treatment.

Radiation: Dose Escalation Radiotherapy
RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU

Procedure: Delayed surgery
Surgery after 8 weeks with TME (total mesorectal excision)

Primary Outcome Measures :
  1. Pathologic complete response [ Time Frame: Through study completion, an average of 2 years ]
    Pathologic evaluation of the surgical specimen

Secondary Outcome Measures :
  1. Disease free survival [ Time Frame: 2 years ]
    Evaluation of disease free survival

  2. Overall survival [ Time Frame: 2 years ]
    Evaluation of overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally advanced rectal cancer, 0-15 cm from anal verge, cT3/4 or cN+

Exclusion Criteria:

  • Metastatic disease, previous chemotherapy, previous radiotherapy, previous malignant non-skin tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02603302

Layout table for location contacts
Contact: Marcos Santos, MD PhD + 55 61 83554308

Layout table for location information
Brasilia Univeristy Hospital Recruiting
Brasília, DF, Brazil, 7676105
Contact: Marcos Santos, MD PHD    +55 61 83554308   
Sponsors and Collaborators
University of Brasilia
Layout table for investigator information
Study Chair: Marcos Santos, MD PhD Brasília University
Layout table for additonal information
Responsible Party: Marcos Santos, MD PhD, University of Brasilia Identifier: NCT02603302    
Other Study ID Numbers: 01
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: June 14, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We may share data in requested by metanalists
Keywords provided by Marcos Santos, University of Brasilia:
rectal cancer
escalated dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases